Suppr超能文献

瑞戈非尼损害线粒体功能,激活腺苷酸活化蛋白激酶,诱导自噬,并导致大鼠肝细胞坏死。

Regorafenib impairs mitochondrial functions, activates AMP-activated protein kinase, induces autophagy, and causes rat hepatocyte necrosis.

作者信息

Weng Zuquan, Luo Yong, Yang Xi, Greenhaw James J, Li Haibo, Xie Liming, Mattes William B, Shi Qiang

机构信息

Division of Systems Biology, National Center for Toxicological Research, Food and Drug Administration, 3900 NCTR Road, Jefferson, AR 72079, USA.

PharmPoint Consulting, 17014 Hersperger Lane, Poolesville, MD 20837, USA.

出版信息

Toxicology. 2015 Jan 2;327:10-21. doi: 10.1016/j.tox.2014.11.002. Epub 2014 Nov 6.

Abstract

The tyrosine kinase inhibitor regorafenib was approved by regulatory agencies for cancer treatment, albeit with strong warnings of severe hepatotoxicity included in the product label. The basis of this toxicity is unknown; one possible mechanism, that of mitochondrial damage, was tested. In isolated rat liver mitochondria, regorafenib directly uncoupled oxidative phosphorylation (OXPHOS) and promoted calcium overload-induced swelling, which were respectively prevented by the recoupler 6-ketocholestanol (KC) and the mitochondrial permeability transition (MPT) pore blocker cyclosporine A (CsA). In primary hepatocytes, regorafenib uncoupled OXPHOS, disrupted mitochondrial inner membrane potential (MMP), and decreased cellular ATP at 1h, and triggered MPT at 3h, which was followed by necrosis but not apoptosis at 7h and 24h, all of which were abrogated by KC. The combination of the glycolysis enhancer fructose plus the mitochondrial ATPase synthase inhibitor oligomycin A abolished regorafenib induced necrosis at 7h. This effect was not seen at 24h nor with the fructose or oligomycin A separately. CsA in combination with trifluoperazine, both MPT blockers, showed similar effects. Two compensatory mechanisms, activation of AMP-activated protein kinase (AMPK) to ameliorate ATP shortage and induction of autophagy to remove dysfunctional mitochondria, were found to be mobilized. Hepatocyte necrosis was enhanced either by the AMPK inhibitor Compound C or the autophagy inhibitor chloroquine, while autophagy inducer rapamycin was strongly cytoprotective. Remarkably, all toxic effects were observed at clinically-relevant concentrations of 2.5-15μM. These data suggest that uncoupling of OXPHOS and the resulting ATP shortage and MPT induction are the key mechanisms for regorafenib induced hepatocyte injury, and AMPK activation and autophagy induction serve as pro-survival pathways against such toxicity.

摘要

酪氨酸激酶抑制剂瑞戈非尼已获监管机构批准用于癌症治疗,尽管产品标签中附有关于严重肝毒性的强烈警告。这种毒性的基础尚不清楚;对一种可能的机制——线粒体损伤机制进行了测试。在分离的大鼠肝线粒体中,瑞戈非尼直接使氧化磷酸化(OXPHOS)解偶联,并促进钙超载诱导的肿胀,再偶联剂6-酮胆甾醇(KC)和线粒体通透性转换(MPT)孔道阻断剂环孢素A(CsA)分别可预防上述情况。在原代肝细胞中,瑞戈非尼在1小时时使OXPHOS解偶联,破坏线粒体膜电位(MMP),并降低细胞ATP水平,在3小时时触发MPT,随后在7小时和24小时时导致坏死而非凋亡,所有这些均被KC消除。糖酵解增强剂果糖与线粒体ATP合酶抑制剂寡霉素A联合使用可消除瑞戈非尼在7小时时诱导的坏死。在24小时时未观察到这种效果,单独使用果糖或寡霉素A时也未观察到。MPT阻断剂CsA与三氟拉嗪联合使用显示出类似效果。发现动员了两种代偿机制,即激活AMP活化蛋白激酶(AMPK)以改善ATP短缺和诱导自噬以清除功能失调的线粒体。AMPK抑制剂化合物C或自噬抑制剂氯喹均可增强肝细胞坏死,而自噬诱导剂雷帕霉素具有很强的细胞保护作用。值得注意的是,所有毒性作用均在2.5 - 15μM的临床相关浓度下观察到。这些数据表明,OXPHOS解偶联以及由此导致的ATP短缺和MPT诱导是瑞戈非尼诱导肝细胞损伤的关键机制,而AMPK激活和自噬诱导作为针对这种毒性的促生存途径。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验